NKGen Biotech today announced that it closed its business combination with Graf Acquisition IV.
The SPAC’s shareholders last week unanimously approved the merger with the clinical-stage biotechnology company, which is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. NKGen is headquartered in Santa Ana, CA.
NKGen’s stock began trading today on The Nasdaq Global Market under the ticker symbol NKGN and warrants on The Nasdaq Capital Market under the ticker symbol NKGNW.
The $160 million deal was announced in April with a minimum $50 million cash condition to close. The cash minimum was later waived by NKGen ahead of the merger vote.
The SPAC’s CEO James Graf has joined NKGen as its interim CFO.
Cooley is acting as legal advisor to NKGen. White & Case is legal advisor to Graf. Read more.
